Xenetic Biosciences (Xenetic Biosciences) Float Percentage Of Total Shares Outstanding : 94.36% (As of Jun. 11, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xenetic Biosciences's float shares is 1.45 Mil. Xenetic Biosciences's total shares outstanding is 1.54 Mil. Xenetic Biosciences's float percentage of total shares outstanding is 94.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xenetic Biosciences's Insider Ownership is 26.24%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xenetic Biosciences's Institutional Ownership is 0.99%.

Xenetic Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Xenetic Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.45	/	1.54
	=	94.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Executives

Grigory G. Borisenko	director	40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov	director	C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow	officer: Chief Financial Officer	C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks	director	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc	10 percent owner	25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110